Sen. Joe Manchin says the FDA needs new leadership, after it signed off on an Alzheimer’s drug that most members of its own advisory panel questioned.
Manchin said the decision “underscores the fact that more of the same leadership at the [FDA] is not the answer,” arguing Biden should nominate a permanent FDA commissioner as soon as possible — and it shouldn’t be Woodcock.
powerful opioid painkillers like OxyContin that helped fuel a nationwide drug abuse epidemic, and claimed Woodcock — a 35-year veteran of the FDA — “has been there for all of it.”have urged Biden to nominate a permanent leader.“Having a permanent agency head in charge to answer … questions on this approval, as well as assure the general public of the FDA’s commitment to public health, is imperative, and Dr. Woodcock is not the right person to lead the FDA,” Manchin wrote.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Authorizes More Covid-19 Vaccine Doses From Troubled Baltimore PlantThe agency cleared 15 million doses, bringing the total doses authorized for export to 25 million, according to a senior U.S. official.
Read more »
First patient receives controversial Biogen Alzheimer's drugA U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc (BIIB.O) before Medicare had even said what it will pay for - and with some doctors upset by its approval last week.
Read more »
GOP crushes Manchin's hopes for elections compromiseJoe Manchin wants to remake Democrats' sweeping elections reform bill. Republicans plan to take it down before he can try.
Read more »
Big insurers are mulling new ways to pay for Biogen's $56,000-per-year Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »